- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05522660
Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer (USZ-STRIKE)
A Multicentre Randomised Open-label Phase III Study of Stereotactic Radiosurgery, in Addition to Standard Systemic Therapy for Patients With Metastatic Melanoma or Newly Diagnosed Metastatic NSCLC and Asymptomatic or Oligo-symptomatic Brain Metastases
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Heidi Roschitzki-Voser, Dr.
- Phone Number: +41 31 511 94 18
- Email: heidi.roschitzki@etop.ibcsg.org
Study Contact Backup
- Name: Susanne Roux
- Phone Number: +41 31 511 94 17
- Email: susanne.roux@etop.ibcsg.org
Study Locations
-
-
-
Napoli, Italy
- Not yet recruiting
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
-
Contact:
- Paolo Ascierto
- Email: p.ascierto@istitutotumori.na.it
-
Perugia, Italy
- Recruiting
- Santa Maria della Misericordia Hospital
-
Contact:
- Mario Mandala
- Email: mario.mandala@unipg.it
-
Roma, Italy
- Not yet recruiting
- Istituto Nazionale Tumori "Regina Elena"
-
Contact:
- Gabriele Minuti
- Email: gabriele.minuti@ifo.it
-
Rome, Italy
- Not yet recruiting
- Policlinico Umberto 1
-
Contact:
- Giuseppe Minniti
- Email: giuseppe.minniti@uniroma1.it
-
Siena, Italy
- Recruiting
- Azienda ospedaliero-universitaria Senese Siena
-
Contact:
- Anna Maria di Giacomo
- Email: a.m.digiacomo@ao-siena.toscana.it
-
-
-
-
-
Amsterdam, Netherlands
- Recruiting
- NKI-AVL
-
Contact:
- Paul Baas
- Email: p.baas@nki.nl
-
-
-
-
-
Bern, Switzerland
- Recruiting
- Inselspital
-
Contact:
- Ekin Ermis
- Email: ekin.ermis@insel.ch
-
Winterthur, Switzerland
- Recruiting
- Kantonsspital Winterthur
-
Contact:
- Natalie Fischer
- Email: natalie.fischer@ksw.ch
-
Zürich, Switzerland
- Recruiting
- Universitatsspital Zurich
-
Contact:
- Michael Weller, Prof.
- Email: Michael.Weller@usz.ch
-
-
-
-
-
London, United Kingdom
- Not yet recruiting
- Royal Marsden (Sutton)
-
Contact:
- Mary O'Brian
- Email: mary.obrien@rmh.nhs.uk
-
Manchester, United Kingdom
- Not yet recruiting
- Christie NHS Manchester
-
Contact:
- Sarah Hughes
- Email: sarah.hughes91@nhs.net
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Newly diagnosed, previously untreated (except for surgery, see below) asymptomatic or oligo-symptomatic brain metastases, e.g., controlled symptomatic seizure disorder. Note: patients with neurological symptoms or signs that require more than a stable dose of 4 mg dexamethasone equivalent for more than one week, are not considered oligo-symptomatic.
Requirements for brain metastases:
- Brain metastases must be previously untreated, except for surgery.
- Prior surgery (including biopsies, resection, and cyst aspiration) for brain metastases is allowed. Residual and measurable disease after surgery is not required, but surgery must have confirmed the diagnosis. An MRI performed within 72 hours post-surgery should be available.
- Number and size of metastases at diagnosis of brain metastases (as per Yamamoto et al.7):
- Maximum 1-10 brain metastases
- At least one brain metastasis must be of ≥5 mm in diameter
- In case of 1-4 brain metastases:
- Longest diameter of largest brain metastasis must be ≤30 mm
- In case of 5-10 brain metastases:
- Largest metastasis must be ≤10 mL in volume and longest diameter must be ≤30 mm
- Maximum cumulative brain metastases volume must be ≤30 mL
Primary disease of histologically confirmed (from primary tumour or from a metastatic lesion, including in the brain) melanoma or NSCLC
Requirements for patients with melanoma:
- Prior treatment, including treatment with immune-checkpoint inhibitors is permitted, but brain metastases must be newly diagnosed and previously untreated (except for surgery).
- BRAF-mutation status, locally assessed, should be known (previous BRAF-targeted therapy is allowed).
Requirements for patients with NSCLC:
- Newly diagnosed, treatment-naïve (except for prior surgery) metastatic NSCLC, with or without a targetable oncogenic driver alteration: sensitising EGFR-mutation (exon 19-del and 21-L858R), ALK- or ROS1-fusion.
- Known PD-L1 expression status (from primary tumour or from a metastatic lesion, including brain)
- Known driver mutation status (from primary tumour or from a metastatic lesion, including brain).
- Age of 18 years or older
- Karnofsky performance status of 60 or more
- Life expectancy >12 weeks
Patients must be candidates for systemic treatment, with one of the following treatment cohorts planned:
- Immune-checkpoint inhibition therapy (combination of ipilimumab and nivolumab) for metastatic melanoma with or without a BRAF-mutation.
- anti-PD-1/L1 monotherapy for metastatic melanoma with or without a BRAF-mutation.
- targeted therapy for metastatic NSCLC with targetable oncogenic driver alteration (EGFR-mutation or ALK- or ROS1-fusion).
- Immune-checkpoint inhibition therapy (including an anti-PD-1/L1 compound) alone or in combination with chemotherapy for metastatic NSCLC without targetable oncogenic driver alteration.
- Women of childbearing potential, including women who had their last menstruation in the last 2 years, must have a negative urinary or serum pregnancy test within 7 days before randomisation.
- Written IC for study participation must be signed and dated by the patient and the investigator prior to any study-related intervention.
Exclusion Criteria:
- Confirmed or probable leptomeningeal metastasis according to EANO ESMO criteria1
Symptomatic brain metastases at time of randomisation, e.g., neurological symptoms or signs that require more than a stable dose of 4 mg dexamethasone equivalent for more than one week.
- Patients must be off steroids or on a stable dose of ≤4 mg dexamethasone equivalent for one week prior to randomisation.
- Patients experiencing seizures controlled by anti-epileptic drugs are eligible.
- Prior whole brain irradiation or focal radiation therapy to the brain
- Prior systemic treatment for brain metastases
- Contra-indication for SRS
- For patients with NSCLC: any previous anticancer systemic therapy other than those under investigation in this study.
- Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.
- Women who are pregnant or in the period of lactation.
- Sexually active men and women of childbearing potential who are not willing to use an effective contraceptive method during the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: standard systemic treatment with stereotactic radiosurgery (SRS)
Arm A
|
The following SRS therapy is foreseen: Two fractionation schedules according to radiation oncologist's preferences and patterns of brain metastases: 1 x 18-22 Gy (18-22 Gy) or 5 x 6 Gy (30 Gy). The following fractionation schedules will be allowed (based on the latest AAPM report on a systematic review and dose response modelling):
Systemic therapy follows the current standard of care, according to the type of the primary tumour.
Other Names:
|
Active Comparator: standard systemic treatment without stereotactic radiosurgery
Arm B
|
Systemic therapy follows the current standard of care, according to the type of the primary tumour.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
CNS-specific PFS, locally assessed as per iRANO criteria
Time Frame: from date of randomization until the date of documented CNS-specific progression, assessed up to 42 months
|
The primary objective of the study is to assess the efficacy in terms of CNS-specific progression-free survival (PFS) of the combination of standard systemic treatment plus SRS versus standard systemic treatment alone in patients with newly diagnosed and untreated (except surgery) asymptomatic or oligo-symptomatic brain metastases from melanoma or non-small cell lung cancer, with indication for systemic therapy.
|
from date of randomization until the date of documented CNS-specific progression, assessed up to 42 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Michael Weller, MD, University of Zurich
- Study Chair: Rolf Stahel, MD, ETOP IBCSG Partners Foundation
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Respiratory Tract Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Central Nervous System Neoplasms
- Nervous System Neoplasms
- Neuroendocrine Tumors
- Nevi and Melanomas
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Brain Neoplasms
- Melanoma
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
Other Study ID Numbers
- ETOP 19-21
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Melanoma
-
H. Lee Moffitt Cancer Center and Research InstituteTurnstone Biologics, Corp.RecruitingMetastatic Melanoma | Conjunctival Melanoma | Ocular Melanoma | Unresectable Melanoma | Uveal Melanoma | Cutaneous Melanoma | Mucosal Melanoma | Iris Melanoma | Acral Melanoma | Non-Cutaneous MelanomaUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IV Melanoma | Mucosal Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Ciliary Body and Choroid Melanoma, Small Size | Iris Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IA Melanoma | Stage IB Melanoma | Stage IIA MelanomaUnited States
-
MelanomaPRO, RussiaRecruitingMelanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma, Stage II | Melanoma, Uveal | Melanoma in Situ | Melanoma, OcularRussian Federation
-
National Cancer Institute (NCI)CompletedStage IV Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Iris Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIB Melanoma | Stage IIC MelanomaUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); University of VirginiaCompletedStage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage III Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IA Skin Melanoma | Stage IB Skin Melanoma | Stage 0 Skin Melanoma | Stage I Skin Melanoma | Stage II Skin MelanomaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); National Comprehensive Cancer NetworkTerminatedRecurrent Melanoma | Stage IV Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIIA Intraocular Melanoma | Stage IIIB Intraocular Melanoma | Stage...United States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IIA MelanomaUnited States
-
Emory UniversityGenentech, Inc.Active, not recruitingStage IV Skin Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Unresectable Melanoma | Stage III Melanoma | Stage IIIA Skin Melanoma | Cutaneous Melanoma, Stage III | Cutaneous Melanoma, Stage IVUnited States
-
BiocadRecruitingMelanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma Metastatic | Melanoma Unresectable | Melanoma AdvancedIndia, Russian Federation, Belarus
Clinical Trials on Stereotactic radiosurgery
-
Accuray IncorporatedUniversity of PittsburghUnknownNon-small Cell Lung CancerUnited States, China
-
University of Alabama at BirminghamCompletedBrain MetastasesUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingMetastatic Malignant Neoplasm in the BrainUnited States, Canada
-
Barretos Cancer HospitalWithdrawn
-
University of ChicagoRecruiting
-
Washington University School of MedicineTerminated
-
Stanford UniversityCompletedBrain (Nervous System) Cancers | Spinal Cord CancerUnited States
-
Tel-Aviv Sourasky Medical CenterUnknown
-
University of LouisvilleJames Graham Brown Cancer CenterTerminatedVertebral MetastasisUnited States
-
M.D. Anderson Cancer CenterNot yet recruiting